Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer
{{output}}
Despite decades of research, pancreatic ductal adenocarcinoma (PDAC) is still one of the most lethal malignant diseases with a devastating 5‑year overall survival of only 4-5%. Indeed, long-term survival was not affected by the introduction of new systemic cy... ...